Kratom and Liver Injury in 2026: The Lab Results and Product Labels a Claim Turns On

Kratom liver injury claims turn on the laboratory file more than the story. Case reports show a recognisable pattern — jaundice, itching, and sharply abnormal liver tests — but also how often another substance muddies the picture. A claim succeeds when the labs, the timeline, and the product label all point the same way.

The regulatory background is worth knowing before you read further, and the plain-English explanations on the Problem Solved channel cover everyday product and money questions in the same practical style as this guide.

  • The U.S. Food and Drug Administration states that kratom is not lawfully marketed in the United States as a drug product, a dietary supplement, or a food additive in conventional food.
  • The FDA has identified liver toxicity among the adverse effects associated with kratom use, alongside seizures and respiratory depression.
  • On July 15, 2025, the FDA issued seven warning letters to companies marketing concentrated 7-hydroxymitragynine (7-OH) products, including tablets, gummies, drink mixes, and shots.
  • A peer-reviewed review of published case reports identified 95 patients with acute adverse effects after kratom use; mitragynine was toxicologically confirmed in 55 of them.
  • In that same review, confounding substances that could have caused or contributed to the effects were found in 32 deceased cases and 7 surviving cases.

What Kratom Liver Injury Means

Kratom is a botanical product made from the leaves of a Southeast Asian tree, sold in the United States as powders, capsules, drinks, and concentrated extracts. Its main active compound is mitragynine, an alkaloid that acts on opioid receptors. 7-hydroxymitragynine (7-OH) is a related alkaloid found in small amounts in the leaf but concentrated to much higher levels in some manufactured products.

Drug-induced liver injury (DILI) means liver damage caused by a drug, supplement, or botanical product rather than by infection or alcohol. In kratom cases the pattern described most often is cholestatic injury: bile flow is impaired, bilirubin rises, and the patient develops jaundice, itching, dark urine, and abdominal discomfort, often with markedly elevated liver enzymes. Naming the pattern matters, because a cholestatic picture with a kratom timeline reads very differently from a viral hepatitis picture — and a claim file that never names the pattern invites the defence to supply its own explanation.

What the FDA Has Actually Said

The FDA's position has two parts, and both matter to a claim. First, the regulatory part: kratom is not lawfully marketed in the United States as a drug, a dietary supplement, or a food additive. No prescription kratom drug has been approved, and no over-the-counter kratom drug has been approved either. That status does not by itself prove that any particular product injured anyone, but it removes the most common defence argument for ordinary supplements — that the product was sold through a lawful, regulated channel with approved labelling.

Second, the safety part: the FDA has warned consumers about serious adverse events associated with kratom, expressly including liver toxicity, seizures, and substance use disorder. In July 2025 the agency escalated against one corner of the market, issuing seven warning letters over concentrated 7-OH products sold in smoke shops, gas stations, and online — tablets, gummies, drink mixes, and shots whose 7-OH levels far exceed anything in natural leaf. A June 2025 warning letter to one such company flagged adverse event reports linking 7-OH products to liver toxicity, seizures, respiratory depression, and fatalities. If the product you used was a concentrated 7-OH product rather than plain leaf powder, that enforcement history is directly relevant to your file.

What the Case Reports Show — and Where They Stop

The medical literature on kratom is built mostly from case reports, not controlled trials. A peer-reviewed review identified 95 patients with acute adverse effects after kratom use; mitragynine was confirmed in 55, of whom 35 were deceased and 20 living. Reported effects spanned the liver, kidneys, heart, lungs, and brain.

Read the same review to its conclusion, because it cuts both ways. The authors found confounding substances — other drugs or compounds that could have caused or contributed to the effects — in 32 deceased cases and 7 surviving cases, and they observed a pattern of weak or inadequate toxicology testing and medical history in the underlying reports. Their conclusion was careful: the literature provides insufficient evidence to support the claim that kratom consumption alone increases the risk of severe acute adverse effects. That sentence is the single most important fact for anyone considering a claim. It does not mean kratom is safe, and it does not mean claims fail. It means the published literature alone will not carry your case — your own file must do the work the literature cannot.

The Lab Results That Decide a Claim

A strong kratom liver-injury file is built in four layers. The first layer is the baseline: any liver labs from before you started using the product. Normal labs before use and abnormal labs during use create the before-and-after contrast that every causation argument needs. The second layer is the injury pattern itself: bilirubin and alkaline phosphatase elevated, the cholestatic signature, with a symptom timeline — when jaundice appeared, when itching started, when you sought care — that matches the labs.

The third layer is dechallenge: what happened after you stopped. In many published cases, liver tests improved within days to weeks of stopping, and complete resolution was typical where the injury was caught early. Document that improvement with dated labs, not memory. The fourth layer is exclusion: a toxicology panel confirming mitragynine, viral hepatitis testing, an alcohol history taken properly, and a full medication list. Every item on that list that comes back negative removes one defence argument. Every item left untested hands the defence a free alternative explanation — which is exactly what the published review warns about. Our guide to the 7-OH crackdown explains why concentrated products face the closest scrutiny, and why the product form you used changes the file.

The Product Label That Decides a Claim

The second half of the file is the product, and it is where most claims quietly fail. Keep the product, the packaging, and the receipt. The label questions that matter are specific: did the product disclose its 7-OH content, or did it sell itself as ordinary kratom leaf while containing a concentrate? Did it carry any liver warning at all? Was the dose per serving stated, and did you use it as directed? A product that hid a concentrate behind a leaf label, or that made no warning while marketing a high-potency extract, presents a very different case from plain leaf powder sold with a stated serving size.

Preservation matters because testing matters. A retained sample can be analysed for alkaloid content, and that analysis can confirm — or contradict — what the label claimed. A claim without a retained product, without packaging, and without a receipt forces the lawyer to prove what you took from memory alone, against a manufacturer that keeps batch records. If you still have the product, store it untouched and photograph the packaging front and back. If you bought online, save the order confirmation and the product page. These unglamorous steps are worth more than any description of symptoms, because symptoms are common to many liver injuries and a tested product is specific to one defendant.

Who Benefits From This — and Who Does Not

Who benefits. A person with a documented cholestatic injury, a clean before-and-after lab record, and a retained concentrated product benefits most, because their file answers the three questions a product lawyer asks first: what was the injury, when did it happen, and what exactly was taken. A person who stopped the product and can show dated lab improvement benefits too, because dechallenge turns a timeline into evidence. And a person who used a 7-OH concentrate benefits from the enforcement record, since regulators have already drawn a public line around those products.

Who does not benefit. A person whose liver injury is fully explained by another documented cause — viral hepatitis, heavy alcohol use, or another hepatotoxic drug taken at the same time — will find the causation argument blocked, however real their suffering. A person who used plain leaf powder with no retained product, no receipt, and no baseline labs faces a long, expensive identification problem before any claim can even be filed. And a person who continued using the product after a diagnosis, without telling their doctor, will find their own file used against them. In each of those situations the honest next step is medical follow-up and a frank file review, not a filing — which is why our article on kratom lawsuits is worth reading before you decide anything.

Frequently Asked Questions

Who benefits from understanding kratom liver-injury claims?

Anyone who developed liver problems while using kratom benefits, because this kind of claim is won or lost on proof, not on symptoms alone. If your medical file ties the injury to a specific product and a clear timeline, you hold the two facts every lawyer and insurer asks for first.

Who does not benefit from a kratom liver-injury claim?

People whose liver injury has a fully documented separate cause — long-term heavy alcohol use, a known viral hepatitis infection, or another drug with the same injury pattern — will struggle, because the defence can explain the injury without kratom. The same is true where no product, receipt, or leftover sample survives: without a product to test, the claim has no defendant to attach to.

How do I start a kratom liver-injury claim?

First, get your full liver records: the first abnormal labs, every follow-up panel, imaging, and any biopsy or specialist note. Second, preserve the product itself, its packaging, and the purchase receipt — do not throw anything away. Third, read our guide to kratom lawsuits, which explains the wider claims landscape, and ask a lawyer experienced in product cases to review the file before any deadline passes.

What lab results matter most in a kratom liver-injury case?

The pattern matters more than any single number. Doctors look for a cholestatic picture — bilirubin and alkaline phosphatase rising out of proportion to other enzymes — together with a timeline: normal labs before use, abnormal labs during use, and improvement after stopping. A toxicology panel that confirms mitragynine, the main kratom alkaloid, and rules out other causes strengthens the file considerably.

Does getting better after stopping prove kratom caused the injury?

It helps, but it does not prove causation on its own. Improvement after stopping, called dechallenge, is one recognised piece of evidence, and doctors weigh it alongside the lab pattern, the dose and duration of use, and what else was ruled out. A file with dechallenge plus a clean toxicology picture is far stronger than either fact alone.

Can I still have a claim if I used other substances too?

Possibly, but the claim gets harder, and honesty about it matters more than embarrassment about it. Published case reviews found confounding substances in many severe cases, so a defence lawyer will look for them. A claim survives that scrutiny when the kratom timeline, the lab pattern, and the product evidence still point the same way after every other substance is accounted for.

General information only — this article explains how product-injury claims are commonly evaluated and is not legal or medical advice. Kratom regulation varies by state and is changing, and a lawyer licensed in your state can apply the current law to your facts. If you have symptoms of liver injury, seek medical care promptly.

Watch on YouTube

Problem Solved on YouTube